1H-吲唑-5-磺酸 | 98550-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 中文名称: 1H-吲唑-5-磺酸
• 中文别名: 1氢-吲唑-5-磺酸
• 英文名称: 1H-indazole-5-sulfonic acid
• 英文别名: 1(2)H-indazole-5-sulfonic acid；1(2)H-Indazol-5-sulfonsaeure
• CAS: 98550-01-7
• 化学式: C₇H₆N₂O₃S
• 分子量: 198.202
• InChiKey: MXWSQZWVKUTEEI-UHFFFAOYSA-N

物化性质

• 熔点：
  >300 °C
• 密度：
  1.681±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.4
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1H-吲唑-5-磺酸 在 三光气 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 3.0h， 生成 1H-吲唑-5-磺酰氯
  参考文献：
  名称：

  CN114773266

  摘要：

  公开号：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 锌 作用下， 生成 1H-吲唑-5-磺酸
  参考文献：
  名称：

  Sureau, Bulletin de la Societe Chimique de France, 1956, p. 101

  摘要：

  DOI：

文献信息

• INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20170342062A1

  公开（公告）日：2017-11-30

  Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma RORγt are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

  本发明涉及式(I)的吲唑磺胺衍生物，其药学上可接受的加盐物，其水合物和/或溶剂合物，以及将其用作视黄醇相关孤儿受体伽玛RORγt的逆向激动剂的用途。还描述了包括这些化合物的药物组合物，以及将其用于治疗RORγt受体介导的炎症性疾病，特别是痤疮、银屑病和/或特应性皮炎的局部和/或口服治疗。
• Pyrrolopyrazine kinase inhibitors
  申请人：Bamberg Joe Timothy

  公开号：US20100267666A1

  公开（公告）日：2010-10-21

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q 1 , R, and X are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及一种新型吡咯吡嗪衍生物的使用，其化学式为I，其中变量Q1、R和X的定义如下所述，该化合物抑制JAK和SYK，并且对于治疗自身免疫和炎症性疾病有用。
• ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：AbbVie Bahamas Limited

  公开号：US20150051239A1

  公开（公告）日：2015-02-19

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  本发明涉及苯磺酰基吡唑啉羧酰胺衍生物作为5-ht6受体拮抗剂，以及制备这些化合物的方法和用于它们合成的新型中间体。本发明还涉及这些化合物和组成物的用途，特别是将它们用于治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情感障碍、偏头痛、阿尔茨海默病、与年龄相关的认知下降、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安静脚症候群、注意力缺陷多动障碍、注意力缺陷障碍、戒断可卡因、乙醇、尼古丁或苯二氮卓类药物的滥用、疼痛、与脊髓损伤或头部损伤相关的疾病、脑积水、功能性肠道紊乱、肠易激综合征、肥胖症和2型糖尿病等方面。这些化合物具有通式（1），其中符号的含义在说明中给出。
• ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS
  申请人：Abbott Healthcare Products B.V.

  公开号：US20140011775A1

  公开（公告）日：2014-01-09

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-ht6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes. The compounds have the general formula (1) wherein the symbols have the meanings given in the description.

  本发明涉及芳基磺酰基吡唑啉羧酰胺衍生物作为5-ht6受体拮抗剂，以及制备这些化合物的方法和用于其合成的新型中间体。本发明还涉及这些化合物和组合物的用途，特别是将其用于治疗帕金森病、亨廷顿舞蹈症、精神分裂症、焦虑症、抑郁症、躁郁症、精神病、癫痫、强迫症、情绪障碍、偏头痛、阿尔茨海默病、年龄相关认知衰退、轻度认知障碍、睡眠障碍、进食障碍、厌食症、贪食症、暴食症、惊恐发作、不安静脚、注意缺陷多动症、戒断可卡因、乙醇、尼古丁或苯二氮平的滥用、疼痛、与脊髓创伤或头部损伤有关的障碍、脑积水、功能性肠道疾病、肠易激综合征、肥胖症和2型糖尿病。这些化合物具有通式（1），其中符号具有描述中所给的含义。
• Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists
  申请人：Abbott Healthcare Products B.V.

  公开号：EP2610247A1

  公开（公告）日：2013-07-03

  This invention concerns arylsulfonyl pyrazoline carboxamidine derivatives as antagonists of 5-HT6 receptors, to methods for the preparation of these compounds and to novel intermediates useful for their synthesis. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes. The compounds have the general formula (1): wherein the symbols have the meanings given in the description.

  本发明涉及作为 5-HT6 受体拮抗剂的芳基磺酰基吡唑啉羧脒衍生物、制备这些化合物的方法以及用于合成这些化合物的新型中间体。睡眠障碍、饮食失调、厌食症、贪食症、暴饮暴食症、惊恐发作、肌痉挛、注意力缺陷多动障碍、注意力缺陷障碍、滥用可卡因、乙醇、尼古丁或苯二氮卓的戒断、疼痛、与脊柱创伤或头部损伤有关的失调、脑积水、功能性肠病、肠易激综合征、肥胖症和 2 型糖尿病。这些化合物的通式为 (1)： 其中符号的含义见说明。